HLN
Haleon PLC
$9.95
▼ 0.9%Updated Today 3:42 PM ET
HLN at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 48/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 5.5% over the last 12 months
Market Cap
$40.75B
P/E
19.04x
Forward P/E (est.)
16.2x
ROE
10.3%
Revenue Growth
-1.8%
EPS Growth
17.6%
Profit Margin
15.1%
FCF Yield
0.5%
Debt / Equity
0.52x
ROIC
8.0%
Interest Coverage
7.09x
Current Ratio
0.92x
Dividend Yield
1.9%
Implied Growth (rev. DCF)
1.7%
Rating Score
48/100
Haleon PLC (HLN) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $40.75B.
In its latest reported year it generated about $14.01B in revenue and $2.12B in net profit.
Our model rates HLN Neutral (48/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (6 years of history).
Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
61.5% average over the last 3 years
±1.6 pts around 61.2% across 6 years
grew in 2 of the last 5 year-over-year periods
positive in 6 of 6 years
8.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what HLN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. HLN trades near $9.95, above its 50-day average ($9.17) and 200-day average ($9.69). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 66 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. HLN's is $0.19 (~1.9% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month HLN found buyers near $8.77 (support) and sellers near $9.82 (resistance); its 52-week range is $8.65–$11.28. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.4× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
3.7%
Revenue moved from $12.56B in 2020 to $14.01B in 2025, a 2.2% compound annual growth rate. The most recent year declined 1.8% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
64.2%
Operating Margin
21.9%
Net Margin
15.1%
ROE
10.3%
Haleon PLC keeps about 15.1% of each sales dollar as net profit, with a 64.2% gross margin and 21.9% operating margin. Return on equity is 10.3% and return on invested capital about 8.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$9.87B
Net Debt
$8.19B
Net Debt / EBITDA
2.67x
Debt / Equity
0.52x
Leverage: debt-to-equity is 0.5x, and operating profit covers interest about 7.1x, with a current ratio of 0.9x. That is a moderate, manageable debt load for most businesses. It carries roughly $9.87B of total debt against $1.68B of cash.
Operating CF
$3.35B
Free Cash Flow
$2.94B
FCF Margin
21.0%
In the latest year Haleon PLC produced about $3.35B of operating cash flow and $2.94B of free cash flow after capital spending. That is a free-cash-flow yield of about 0.5% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The dividend is being paid, but coverage or consistency is thinner than an income investor should rely on without a closer look.
Dividend yield
1.9%
Per share (latest FY)
$15151.10
Total paid (latest FY)
$777.24M
History on record
6 years
dividend uses 26% of free cash flow
37% of net income paid out
total dividends increased 2 years in a row
payout was cut at least once in the last 6 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
19.04x
P/S
2.88x
P/B
2.03x
EV / EBITDA
13.9x
HLN trades at 19.0x trailing earnings (about 16.2x on estimated forward earnings), 2.9x sales, and 2.0x book value. Reverse-engineering today's price implies the market expects roughly 1.7% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$4.04
Current price
$9.95
Starting FCF (latest 10-K)
$2.94B
Growth, years 1–5
-1.8%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where HLN sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How HLN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), HLN ranks #52 of 324 by our overall rating. It trades at a discount versus the sector on earnings (19x P/E vs. 25.4x median) with a lower return on equity (10.3% vs. 14.1%) and slower revenue growth (-1.8% vs. 7.6%).
P/E vs sector
19x
median 25.4x
ROE vs sector
10.3%
median 14.1%
Growth vs sector
-1.8%
median 7.6%
Sector rank
#52
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $9.95 today · expected CAGR -8% – 3%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $14.43B | $14.86B | $15.31B | $15.77B | $16.24B |
| Net income | $2.16B | $2.23B | $2.30B | $2.36B | $2.44B |
| EPS | $0.53 | $0.54 | $0.56 | $0.58 | $0.59 |
| Share price (low) | $5.81 | $5.99 | $6.17 | $6.35 | $6.54 |
| Share price (high) | $10.04 | $10.34 | $10.65 | $10.97 | $11.30 |
| CAGR (low–high) | -42% / 1% | -22% / 2% | -15% / 2% | -11% / 2% | -8% / 3% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for HLN:
- High net margins (15.1%) point to pricing power or efficiency.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against HLN:
- Revenue growth is slow/negative (-1.8%), limiting the upside engine.
- Limited free cash flow at today's price.
Growth risk — sluggish revenue (-1.8%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Haleon PLC is a large-cap health care business with shrinking revenue, with solid profitability, and a sound balance sheet. It trades at 19.0x earnings, which our model scores Neutral (48/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 26 Wall Street analysts covering HLN recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-7 pts of buy ratings).
Latest SEC Filings
HLN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
HLN — frequently asked questions
Is HLN a good stock to buy?
We don't give buy or sell advice. Our model rates Haleon PLC Neutral (48/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is HLN's rating on The Stocks School?
Haleon PLC currently scores 48/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does HLN's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Haleon PLC's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for HLN calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this HLN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell HLN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.